Highlights

• EchoIQ shares rose 6.79% to AUD 1.73 during the morning session on 2 July 2026.

• The company executed a definitive exclusive data licensing agreement with Advara HeartCare.

• The agreement provides access to between 500,000 and 1,000,000 de-identified echocardiography studies.

• The dataset includes echocardiographic images and linked clinical information from a broad patient population.

• EchoIQ expects the data to support EchoSolv development, AI model training and future product validation.

• The agreement has an initial three-year term, with an option to extend for another three years.

EchoIQ Ltd (ASX:EIQ) shares moved higher during the morning session on 2 July 2026 after the company announced a strategic data licensing partnership with Advara HeartCare. The stock rose 6.79% to AUD 1.73, adding AUD 0.11 for the session. Over the past year, EchoIQ remains up 565.38%, reflecting a gain of AUD 1.47.

The latest update appears favourable, as EchoIQ has secured binding exclusivity under a definitive data licensing agreement with Advara HeartCare, Australia’s largest private cardiovascular diagnostics provider. The agreement gives EchoIQ access to a substantial de-identified echocardiography dataset, expected to comprise between 500,000 and 1,000,000 studies, along with associated clinical datasets. The company said the data is expected to enhance product development, training and validation of next-generation cardiovascular AI products.

EchoIQ is an artificial intelligence and medical technology company focused on cardiovascular diagnostics. Its EchoSolv platform is designed to support clinical decision-making by applying AI to cardiovascular data. The company’s strategy relies heavily on access to large-scale clinical and imaging datasets, which can be used to develop, refine and validate AI models across different cardiovascular conditions.

Exclusive Advara Agreement Expands EchoIQ’s Data Access

The key element of the announcement is EchoIQ’s executed definitive exclusive data licensing agreement with Advara HeartCare.

Under the agreement, EchoIQ will receive exclusive access to a large dataset of de-identified echocardiography studies and related clinical information sourced through Advara’s national network. The dataset is expected to include between 500,000 and 1,000,000 de-identified echocardiographic studies.

The data will include echocardiographic images as well as linked clinical information. This may include de-identified patient demographics where applicable and appropriate, referral pathways, diagnostic findings and relevant clinical outcomes.

For an AI-driven medical technology company, access to this type of data is important because algorithm development depends on both scale and quality. EchoIQ said the dataset is expected to materially strengthen its future product development capabilities by supporting model training, refinement and validation across multiple cardiovascular indications.

Advara Brings National Scale and Clinical Depth

Advara HeartCare is described by EchoIQ as Australia’s largest private cardiovascular diagnostics provider. The organisation operates a national network of cardiovascular clinics and diagnostic facilities, delivering echocardiography and other cardiac imaging services across Australia.

Advara supports more than 750,000 patient interactions annually and provides services across prevention, diagnostics, treatment, clinical research and data-driven innovation. Its operations include cardiologists, specialist clinics, diagnostic services and clinical research programs.

Through this national activity, Advara has built a significant repository of real-world cardiovascular imaging and clinical information. EchoIQ noted that these data have been generated through routine clinical care and ethically conducted research, and are managed under clinical governance, privacy and information security frameworks.

The scale and diversity of Advara’s clinical activity make the dataset relevant for EchoIQ’s future AI development plans, particularly as the company works to expand beyond single-use applications toward broader cardiovascular diagnostic and predictive tools.

Dataset Expected to Support EchoSolv Product Development

EchoIQ said the Advara dataset is expected to materially enhance future development of its EchoSolv platform and next-generation cardiovascular AI products.

The company believes that large, high-quality imaging datasets will become increasingly important as cardiovascular AI evolves. In its view, AI in cardiology is moving from single-disease applications toward broader multi-condition diagnostic and predictive platforms.

The Advara dataset is expected to provide a substantial imaging resource for algorithm development. It may help EchoIQ train AI models on real-world imaging data, refine model performance and validate future products across a wider range of cardiovascular conditions.

The agreement also includes intellectual property protections, with EchoIQ retaining ownership of all AI outputs. It also includes detailed confidentiality and data security obligations, along with comprehensive data quality and de-identification standards.

Initial delivery of licensed data remains subject to Human Research Ethics Committee approval and agreement on data quality specifications.

NEDA Relationship Remains Complementary

EchoIQ also highlighted that the Advara agreement complements its existing relationship with the National Echo Database Australia, known as NEDA.

According to the company, NEDA provides one of the world’s largest longitudinal cardiovascular outcomes datasets and remains central to EchoIQ’s clinical validation, evidence-generation and regulatory strategy.

The Advara dataset serves a different but complementary role. While NEDA is focused on longitudinal outcomes and validation, Advara provides extensive real-world imaging data that is suited to AI development and model training.

Together, EchoIQ expects these two data assets to create a differentiated cardiovascular AI ecosystem covering product discovery, algorithm development, clinical validation, regulatory evidence generation and commercial deployment.

This combination of large-scale imaging data and longitudinal clinical outcomes data is expected to strengthen EchoIQ’s competitive position and support the expansion of its future product pipeline.

Agreement Covers Initial Three-Year Term

The data licensing agreement has an initial term of three years. It also includes an option to extend for a further three years.

However, the agreement remains subject to certain conditions before initial data delivery. These include Human Research Ethics Committee approval and agreement on data quality specifications.

The agreement includes binding exclusivity provisions, which are important because they limit access to the dataset under the agreed framework. EchoIQ said this exclusive access strengthens its competitive position and supports the expansion of its future product pipeline.

The arrangement also sets out data governance requirements, including de-identification standards, confidentiality protections and information security obligations.

Management Highlights Strategic Importance

EchoIQ Chief Executive Officer Dustin Haines said securing access to a dataset of this scale is strategically important for the company and represents a meaningful enhancement to its long-term AI development capabilities.

He said NEDA continues to provide a world-class platform for clinical validation and outcomes research, while the Advara dataset brings large-scale real-world imaging data that can be used to train, refine and develop future cardiovascular AI products.

He added that the combination of the two data assets strengthens EchoIQ’s competitive position, expands future product development opportunities and supports the company’s strategy of building a cardiovascular AI platform backed by proprietary and difficult-to-replicate datasets.

Advara HeartCare Chief Executive Officer Dr David O’Donnell said Advara’s purpose is to improve Australia’s heart health through clinical excellence, research and innovation. He said Advara generates substantial real-world cardiovascular clinical and imaging data, which, when properly governed and de-identified, can support the responsible development and validation of technologies intended to improve patient care.

He also noted that Advara sees AI as having the potential to complement clinicians in delivering quality care to patients.

Share Price Reaction Reflects Data-Driven AI Focus

EchoIQ’s share price gain on 2 July 2026 followed an announcement directly linked to its product development strategy.

For AI medical technology companies, data access is a key development input. The Advara agreement provides EchoIQ with a large pool of de-identified echocardiographic images and related clinical information, which the company expects to use in training and validating future AI models.

The scale of the dataset is notable, with expected access to between 500,000 and 1,000,000 studies. The agreement also strengthens EchoIQ’s position alongside its existing NEDA relationship, giving the company access to both large-scale imaging data and longitudinal outcomes data.

While the announcement is favourable from a strategic development perspective, investors should note that it does not represent a direct product approval or immediate revenue update. The initial data delivery remains subject to ethics approval and agreement on data quality specifications.

What This Means for Investors?

EchoIQ’s latest update appears to have supported the rise in its share price because it adds a large and exclusive data asset to the company’s cardiovascular AI development platform. The agreement with Advara HeartCare provides access to up to 1 million de-identified echocardiography studies, along with relevant clinical datasets, which may support future EchoSolv development and next-generation AI products. For investors, the key focus will be how EchoIQ uses this dataset alongside NEDA to train, validate and expand its product pipeline. However, the agreement remains subject to HREC ethics approval and final data quality specifications before initial delivery.